Eric Vermeulen
Overview
Explore the profile of Eric Vermeulen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alessandrini E, Brako F, Scarpa M, Lupo M, Bonifazi D, Pignataro V, et al.
Pharmaceutics
. 2021 Jun;
13(5).
PMID: 34063499
The paucity of evidence-based data on formulation characteristics preferred by the children is known to limit the design of tailored paediatric dosage forms. The European Paediatric Translational Research Infrastructure (EPTRI)...
2.
Aurich B, Vermeulen E, Elie V, Driessens M, Kubiak C, Bonifazi D, et al.
BMJ Paediatr Open
. 2021 Jan;
4(1):e000847.
PMID: 33437878
Obtaining informed consent from parents of critically ill neonates can be challenging. The parental decision-making process is influenced by the severity of the child's condition, the benefit-risk balance, their emotional...
3.
Vermeulen E, Karsenberg K, van der Lee J, de Wildt S
Clin Transl Sci
. 2019 Oct;
13(1):11-13.
PMID: 31647179
No abstract available.
4.
van Oort P, Maaskant J, Smeulers M, van Oostrum N, Vermeulen E, van Goudoever J
J Pediatr Nurs
. 2019 Mar;
46:e44-e51.
PMID: 30904344
Purpose: Factors that promote parents' participation during medical rounds on their hospitalized child have not been fully addressed. The aim of this study was to identify factors that promote the...
5.
Rebers S, Vermeulen E, Brandenburg A, Aaronson N, Schmidt M
Public Health Genomics
. 2018 Sep;
21(1-2):27-36.
PMID: 30199881
Background: Residual tissue samples, i.e., samples excised for diagnosis or during treatment, are commonly used for medical research. In the Netherlands, they can be used provided the patient did not...
6.
Rare disease registries: potential applications towards impact on development of new drug treatments
Jansen-van der Weide M, Gaasterland C, Roes K, Pontes C, Vives R, Sancho A, et al.
Orphanet J Rare Dis
. 2018 Sep;
13(1):154.
PMID: 30185208
Background: Low prevalence, lack of knowledge about the disease course, and phenotype heterogeneity hamper the development of drugs for rare diseases. Rare disease registries (RDRs) can be helpful by playing...
7.
Vermeulen E, Rebers S, Aaronson N, Brandenburg A, van Leeuwen F, Schmidt M
Genet Test Mol Biomarkers
. 2018 Feb;
22(3):178-186.
PMID: 29461872
Aims: To investigate the attitudes of patients toward the return of individual research results from scientific research with residual tissue. Methods And Findings: We recruited 1319 patients from 6 Dutch...
8.
Vermeulen E, van den Anker J, Della Pasqua O, Hoppu K, van der Lee J
J Pharm Pharmacol
. 2016 Sep;
69(4):439-447.
PMID: 27671925
Objectives: In children, there is often lack of sufficient information concerning the pharmacokinetics (PK) and pharmacodynamics (PD) of a study drug to support dose selection and effective evaluation of efficacy...
9.
Vermeulen E, Boeckhout M, Zielhuis G, Bakker R, Janssens A, Schmidt M
Ned Tijdschr Geneeskd
. 2014 Jan;
158(5):A6653.
PMID: 24472337
Biobanks should return clinically significant and actionable research findings to donors who have given physical material to the biobank. Because the clinical significance of a research finding is hard to...
10.
Vermeulen E, Henneman L, van El C, Cornel M
Eur J Public Health
. 2013 Sep;
24(5):768-75.
PMID: 24068545
Background: Genetic testing and family history assessment can be used as an aid in the prevention of common chronic diseases. The aim of this study was to determine public attitudes...